The Future of Peptide Therapy: Clinical Trials, FDA Pathways, and What Is Moving From Research to Medicine

Peptides occupy a growing space between small-molecule drugs and large biologics. As of 2025, over 80 peptide-based drugs have received FDA approval, and several hundred more are in various stages of clinical development. This post examines which peptide candidates are advancing through clinical trials, how the FDA evaluates peptide therapeutics, and where the field stands in translating research findings into approved medicines.

The Peptide Register tracks these developments as an independent research reference, cataloguing published evidence, regulatory status, and mechanism of action profiles across the peptide landscape. For foundational context on how peptides differ from other molecule classes, see our overview of how peptides compare to proteins, hormones, and small molecules.

The Current Clinical Trial Landscape for Peptides

More than 150 peptide therapeutics were in active clinical trials globally as of early 2025. These span oncology, metabolic disease, infectious disease, and rare genetic conditions. The GLP-1 receptor agonist class, which includes semaglutide and tirzepatide, represents one of the most commercially significant peptide therapy categories in modern medicine. Semaglutide alone generated over $20 billion in annual revenue by 2024, driven by FDA approvals for type 2 diabetes and chronic weight management.

Beyond the GLP-1 class, peptide candidates under investigation include melanocortin receptor agonists for obesity, antimicrobial peptides for drug-resistant infections, and tumour-targeting peptide-drug conjugates in oncology. More than 150 peptide therapeutics were in active clinical trials globally as of early 2025, according to industry pipeline analyses. However, it is important to note that the majority of candidates entering Phase 1 trials do not ultimately receive regulatory approval. Attrition rates for peptide drug candidates remain substantial, with many failing due to bioavailability limitations, off-target effects, or insufficient efficacy in larger trials.

FDA Regulatory Pathways for Peptide Drugs

The FDA regulates peptide therapeutics primarily through two centres: the Center for Drug Evaluation and Research (CDER) for most synthetic peptides, and the Center for Biologics Evaluation and Research (CBER) for certain larger or recombinant peptide products. The FDA classifies most synthetic peptides under 40 amino acids as drugs rather than biologics. This classification affects the approval pathway, patent protections, and the route to generic or follow-on competition.

In 2023, the FDA published updated guidance on the chemistry, manufacturing, and controls (CMC) requirements for synthetic peptide drugs, reflecting growing interest in standardising quality benchmarks. The FDA published updated CMC guidance for synthetic peptide drugs in 2023, aimed at standardising manufacturing quality expectations. Peptides seeking approval must demonstrate safety and efficacy through the standard Investigational New Drug (IND) and New Drug Application (NDA) process, or through the Biologics License Application (BLA) pathway where applicable.

One area of regulatory tension involves compounded peptides. The FDA's Category 1 and Category 2 lists under the Federal Food, Drug, and Cosmetic Act determine which bulk drug substances may be used in compounding. Several peptides previously available through compounding pharmacies, including certain growth hormone secretagogues, have faced increased scrutiny. The regulatory environment around peptide scheduling and access varies significantly by jurisdiction, and researchers should verify current status in their region.

Peptides Advancing From Preclinical to Clinical Stages

Several peptide candidates frequently discussed in research communities remain at early stages of clinical translation. BPC-157, for example, has an extensive preclinical literature but lacks published Phase 2 or Phase 3 human trial data as of mid-2025. BPC-157 has extensive preclinical evidence but lacks published Phase 2 or Phase 3 human clinical trial data as of mid-2025. Similarly, thymosin beta-4 has been investigated in early-phase wound healing trials, but large-scale confirmatory studies remain limited.

By contrast, some peptide classes have moved rapidly through clinical development. Tirzepatide, a dual GIP/GLP-1 receptor agonist peptide, received FDA approval in 2022 for type 2 diabetes and in 2023 for chronic weight management. Tirzepatide received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. Retatrutide, a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors, showed significant weight reduction in Phase 2 trials published in 2023, though Phase 3 results are still pending.

Retatrutide, a triple-agonist peptide, showed significant weight reduction in Phase 2 trial data published in 2023. These results require confirmation in larger Phase 3 studies before any regulatory submission.

What the Pipeline Means for the Field

The peptide therapy pipeline is broader and more active than at any previous point. The global peptide therapeutics market was valued at approximately $42 billion in 2024 according to multiple industry reports. The global peptide therapeutics market was valued at approximately $42 billion in 2024 according to industry analyses. However, a wide gap persists between the peptides discussed in online communities and those with robust clinical evidence supporting regulatory approval.

Readers evaluating peptide research should carefully distinguish between preclinical promise and clinical validation. Understanding study design, species differences in dosing, and effect sizes is essential; our guide on how to read peptide research covers these considerations in detail. The Peptide Register's peptide database provides structured profiles including regulatory status, published evidence, and mechanism of action for individual compounds.

The pace of peptide clinical development is accelerating, but the distance between a promising animal study and an approved human therapy remains significant. For most peptides outside the GLP-1 receptor agonist class, the evidence base is still early-stage, and claims of therapeutic benefit should be evaluated with appropriate caution.